Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered NK cells take on tough cancers in first human test

NCT ID NCT07621471

Disease control Sponsor: Genovn Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of immune cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own natural killer (NK) cells that have been genetically modified to produce IL-15, a protein that helps them survive and fight cancer longer. The study will enroll 12 participants to check safety and find the right dose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
genetically engineered natural killer (NK) cells that produce IL-15
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat solid tumors that have spread.
What could go wrong
This is a very early, small trial (12 people) focused on safety, not effectiveness. The treatment may not shrink tumors or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-70 years; 2. ECOG 0-1; 3. histopathologically confirmed metastatic or recurrent solid tumors (breast, liver, lung, etc.); 4. failed prior standard therapy; 5. \>=1 measurable lesion per RECIST 1.1; 6. adequate bone marrow, liver, kidney, and coagulation function; 7. recovered from prior treatment toxicities; 8. signed informed consent. Exclusion Criteria: 1. Pregnancy/lactation; 2. other malignancy within 5 years (except cured localized tumors); 3. active autoimmune disease or immunodeficiency; 4. uncontrolled cardiovascular disease or infection; 5. active TB; 6. positive HBsAg/HBcAb or HCV antibody (unless viral load undetectable); 7. positive syphilis antibody; 8. major surgery or vaccination within 28 days; 9. prior cell therapy; 10. severe allergy to study drugs; 11. investigator judged unsuitable.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic cancer Solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xinqiao Hospital

    Chongqing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.